Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Transplant RejectionRenal Transplantation
Interventions
DRUG

Sirolimus

Sirolimus, 1 mg, white, triangular tablets, daily dose, dosages of any of these medications must be stable for at least 2 weeks prior to screening and continue with no change until completion of the last PK sample collection.

Trial Locations (2)

200127

Pfizer Investigational Site, Shanghai

400038

Pfizer Investigational Site, Chongqing

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01236378 - Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients | Biotech Hunter | Biotech Hunter